HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.

Abstract
Very small size proteoliposomes (VSSP) constitute a complex of very small size proteoliposomes that includes proteins, lipids, CpG and gangliosides tumor-associated that provides a potential target for cancer immunotherapy. This compound has been described to stimulate the humoral and cellular response, dendritic cells (DC) activation and differentiation of T-helper cells, specially, in immunocompromised patients with cancer status. This work deals with the stimulating capacity of the VSSP to reach a humoral response when they are used as a component in a peptidic vaccine based on the gonadotrophin releasing hormone (GnRH). This study was carried out in male Copenhagen rats, which were immunized with 750μg of the GnRH mimetic peptide (GnRHm1-TT) with or without the VSSP. The mixtures were always emulsified with the oil adjuvant Montanide ISA 51. The anti GnRH seroconversion analysis revealed that the group immunized with the peptide GnRHm1-TT/VSSP developed a strong anti GnRH seroconversion. These antibody levels proved to be significant superior to those reached by the use of the GnRHm1-TT peptide solely emulsified in Montanide. Post-mortem analysis on the Testosterone ablation target organs (prostate and testicles) yielded a sudden decrease in their size and weight in respect to the control group. On the other hand, the group submitted to the use of GnRHm1-TT/VSSP, showed a significant difference in the reduction of these target organs in comparison with the group only immunized with GnRHm1-TT adjuvated in Montanide ISA 51. These values turned to be of p=0.023 and p=0.009 in the prostate and testicles respectively. These findings foreground the VSSP as a useful immunopotentiator to be used as part of a GnRH based vaccine to treat prostate cancer.
AuthorsFranklin Fuentes Aguilar, Jesús Junco Barranco, Eddy Bover Fuentes, Lesvia Calzada Aguilera, Yovisleydis Lopez Sáez, María Dolores Castro Santana, Eulogio Pimentel Vázquez, Roberto Basulto Baker, Osvaldo Reyes Acosta, Hilda Garay Pérez, Gerardo Guillén Nieto
JournalVaccine (Vaccine) Vol. 30 Issue 46 Pg. 6595-9 (Oct 12 2012) ISSN: 1873-2518 [Electronic] Netherlands
PMID22921738 (Publication Type: Journal Article)
CopyrightCopyright © 2012 Elsevier Ltd. All rights reserved.
Chemical References
  • Adjuvants, Immunologic
  • Antibodies
  • Cancer Vaccines
  • Oleic Acids
  • Proteolipids
  • montanide ISA 51
  • proteoliposomes
  • Gonadotropin-Releasing Hormone
  • Mannitol
Topics
  • Adjuvants, Immunologic (administration & dosage)
  • Animals
  • Antibodies (blood)
  • Cancer Vaccines (administration & dosage, immunology)
  • Gonadotropin-Releasing Hormone (administration & dosage, immunology)
  • Male
  • Mannitol (administration & dosage, analogs & derivatives)
  • Oleic Acids (administration & dosage)
  • Prostatic Neoplasms (immunology, pathology, therapy)
  • Proteolipids (administration & dosage)
  • Rats

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: